Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00881621
Recruitment Status : Terminated (slow enrollment)
First Posted : April 15, 2009
Results First Posted : March 6, 2017
Last Update Posted : March 6, 2017
Information provided by (Responsible Party):
Ruth He, Georgetown University

April 13, 2009
April 15, 2009
March 15, 2015
March 6, 2017
March 6, 2017
August 2009
December 2012   (Final data collection date for primary outcome measure)
Overall Survival [ Time Frame: 24 months ]
Time of study entry to time of death
Overall Survival [ Time Frame: 2.5 years ]
Complete list of historical versions of study NCT00881621 on Archive Site
  • Clinical Benefit Response [ Time Frame: 3 months ]
    number of participants who had stable disease or partial response or complete response per Response Evaluation Criteria In Solid Tumors. Complete Response: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Stable Disease: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
  • Progression Free Survival [ Time Frame: 24 months ]
    Time of study entry to cancer progression.
  • Adverse Events [ Time Frame: 2 years ]
    Grade 3 or 4 toxicities
  • Clinical Benefit Response [ Time Frame: 2.5 years ]
  • Objective Response [ Time Frame: 2.5 years ]
  • Adverse Events [ Time Frame: 2 years ]
Not Provided
Not Provided
Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer
Phase II Study of Lapatinib and Capecitabine in 2nd Line Treatment of Locally Advanced/Metastatic Pancreatic Cancer

Patients are being asked to participate in this study who have locally advanced or metastatic pancreatic cancer (cancer of the pancreas that has spread to another part of the body) that has gotten worse after first-line chemotherapy.

The purpose of this study is to see if the drugs, Capecitabine and Lapatinib (two chemotherapy agents), prolong survival and improve quality of life as compared to supportive care alone.

Lapatinib in combination with a drug called capecitabine, has been approved by the Food and Drug Administration (FDA) for the treatment of metastatic breast cancer. It has not yet been approved to treat this type of cancer. Both of these drugs are pills.

This research is being done because it is not known if the combination of Capecitabine and Lapatinib is better than supportive care alone for pancreatic cancer.

This is an open-label single-arm Phase II trial for patients with metastatic pancreatic cancer who have failed first line Gemcitabine-based therapy. Patients will be treated with a combination of Capecitabine and Lapatinib, a dual tyrosine-kinase inhibitor of EGFR and HER-2.
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Pancreas Cancer
Drug: Lapatinib and Capecitabine
Lapatinib 1250-mg PO daily one hour before or after meals Capecitabine 1000 mg/m2 PO twice daily on days 1-14 of 21-day cycle for a total of 8 cycles
Other Names:
  • Tykerb
  • GW572016
Experimental: Lapatinib and Capecitabine
Intervention: Drug: Lapatinib and Capecitabine
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
June 2013
December 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically confirmed adenocarcinoma of the pancreas
  • Prior failed 1st line gemcitabine therapy for metastatic disease or relapsed within six months of completion of gemcitabine adjuvant therapy
  • Prior capecitabine or 5fu is allowed in the setting of radiation
  • Must either be able to swallow or receive enteral nutrition via gastrostomy feeding tube
  • Cardiac ejection fraction within institutional range of normal as measured by echocardiogram
  • ECOG performance status 0-2
  • Signed informed consent form
  • Adequate hepatic, bone marrow, and renal function

Exclusion Criteria:

  • Any prior treatment with lapatinib, or any anti-HER2 treatment or any anti-EGFR treatment
  • Not recovered from adverse events to a toxicity grade </= 1 due to prior chemotherapy
  • More than one prior chemotherapy regimens
  • Known brain metastases, uncontrolled seizure disorders, encephalitis, or multiple sclerosis
  • HIV positive on antiretroviral therapy
  • Pregnant or lactating
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to lapatinib or capecitabine
  • Malabsorption syndrome or uncontrolled inflammatory GI disease (Crohn's or ulcerative colitis)
  • Known history of uncontrolled or symptomatic angina, arrhythmia, or congestive heart failure
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/ social situations that would limit compliance with study requirements
  • Known dihydropyrimidine dehydrogenase deficiency
  • Concurrent malignancy unless the subject has been curatively treated and disease free for >/= 2 years or the cancer was non-melanoma skin cancer or early cervical cancer.
  • Creatinine clearance < 30 mL/min
  • Absolute neutrophil count < 1500, platelets < 75,000
  • Transaminases > 3.0 times the upper limit of normal, except in known hepatic metastasis, wherein they must be < 5.0 times the upper limit of normal
  • Total bilirubin > 1.5 times the ULN, > 2.5 x ULN if patient has Gilbert's syndrome
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
United States
IND #103,981 ( Other Identifier: FDA )
2008-437 ( Other Identifier: IRB )
Not Provided
Plan to Share IPD: No
Ruth He, Georgetown University
Georgetown University
Principal Investigator: Ruth He, MD, PhD Georgetown University
Georgetown University
January 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP